New therapeutic targets in the management of urothelial carcinoma of the bladder
Einar F Sverrisson, Patrick N Espiritu, Philippe E SpiessDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, r...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-03-01
|
Series: | Research and Reports in Urology |
Online Access: | http://www.dovepress.com/new-therapeutic-targets-in-the-management-of-urothelial-carcinoma-of-t-a12337 |
id |
doaj-1213022982c740409dafd43eb7414b60 |
---|---|
record_format |
Article |
spelling |
doaj-1213022982c740409dafd43eb7414b602020-11-25T01:16:23ZengDove Medical PressResearch and Reports in Urology2253-24472013-03-012013default5365New therapeutic targets in the management of urothelial carcinoma of the bladderSverrisson EFEspiritu PNSpiess PEEinar F Sverrisson, Patrick N Espiritu, Philippe E SpiessDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern urological clinical practice. New therapies target biomolecular pathways and cellular mediators responsible for regulating cell growth and metabolism, both of which are frequently overexpressed in malignant urothelial cells, with the intent of inducing cell death by limiting cellular metabolism and growth, creating an immune response, or selectively delivering or activating a cytotoxic agent. These new and novel therapies may offer a potential for reduced toxicity and an encouraging hope for better treatment outcomes, particularly for a disease often refractory or not amenable to the current therapeutic approaches.Keywords: targeted therapy, intravesical agents, systemic therapieshttp://www.dovepress.com/new-therapeutic-targets-in-the-management-of-urothelial-carcinoma-of-t-a12337 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sverrisson EF Espiritu PN Spiess PE |
spellingShingle |
Sverrisson EF Espiritu PN Spiess PE New therapeutic targets in the management of urothelial carcinoma of the bladder Research and Reports in Urology |
author_facet |
Sverrisson EF Espiritu PN Spiess PE |
author_sort |
Sverrisson EF |
title |
New therapeutic targets in the management of urothelial carcinoma of the bladder |
title_short |
New therapeutic targets in the management of urothelial carcinoma of the bladder |
title_full |
New therapeutic targets in the management of urothelial carcinoma of the bladder |
title_fullStr |
New therapeutic targets in the management of urothelial carcinoma of the bladder |
title_full_unstemmed |
New therapeutic targets in the management of urothelial carcinoma of the bladder |
title_sort |
new therapeutic targets in the management of urothelial carcinoma of the bladder |
publisher |
Dove Medical Press |
series |
Research and Reports in Urology |
issn |
2253-2447 |
publishDate |
2013-03-01 |
description |
Einar F Sverrisson, Patrick N Espiritu, Philippe E SpiessDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USAAbstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern urological clinical practice. New therapies target biomolecular pathways and cellular mediators responsible for regulating cell growth and metabolism, both of which are frequently overexpressed in malignant urothelial cells, with the intent of inducing cell death by limiting cellular metabolism and growth, creating an immune response, or selectively delivering or activating a cytotoxic agent. These new and novel therapies may offer a potential for reduced toxicity and an encouraging hope for better treatment outcomes, particularly for a disease often refractory or not amenable to the current therapeutic approaches.Keywords: targeted therapy, intravesical agents, systemic therapies |
url |
http://www.dovepress.com/new-therapeutic-targets-in-the-management-of-urothelial-carcinoma-of-t-a12337 |
work_keys_str_mv |
AT sverrissonef newtherapeutictargetsinthemanagementofurothelialcarcinomaofthebladder AT espiritupn newtherapeutictargetsinthemanagementofurothelialcarcinomaofthebladder AT spiesspe newtherapeutictargetsinthemanagementofurothelialcarcinomaofthebladder |
_version_ |
1725149971066388480 |